Taysha Gene Therapies (TSHA) Short Interest Ratio & Short Volume $1.28 +0.04 (+2.81%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Taysha Gene Therapies Short Interest DataTaysha Gene Therapies (TSHA) has a short interest of 21.63 million shares, representing 10.85% of the float (the number of shares available for trading by the public). This marks a -14.34% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.8, indicating that it would take 9.8 days of the average trading volume of 2.67 million shares to cover all short positions.Current Short Interest21,630,000 sharesPrevious Short Interest25,250,000 sharesChange Vs. Previous Month-14.34%Dollar Volume Sold Short$30.07 millionShort Interest Ratio9.8 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares205,002,000 sharesShort Percent of Float10.85%Today's Trading Volume832,896 sharesAverage Trading Volume2,670,942 sharesToday's Volume Vs. Average31% Short Selling Taysha Gene Therapies? Sign up to receive the latest short interest report for Taysha Gene Therapies and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTSHA Short Interest Over TimeTSHA Days to Cover Over TimeTSHA Percentage of Float Shorted Over Time Remove Ads Taysha Gene Therapies Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202521,630,000 shares $30.07 million -14.3%10.8%9.8 $1.39 3/15/202525,250,000 shares $43.43 million -1.1%12.7%12.5 $1.72 2/28/202525,530,000 shares $40.85 million +1.8%12.8%10.9 $1.60 2/15/202525,090,000 shares $40.90 million +4.2%12.6%8.1 $1.63 1/31/202524,080,000 shares $36.12 million +0.5%N/A5.7 $1.50 1/15/202523,950,000 shares $39.04 million -7.5%N/A5.4 $1.63 12/31/202425,880,000 shares $44.77 million +18.3%N/A6 $1.73 12/15/202421,880,000 shares $45.29 million +39.6%N/A5.1 $2.07 11/30/202415,670,000 shares $50.77 million -0.5%N/A3.8 $3.24 11/15/202415,750,000 shares $32.45 million -10.7%N/A4.4 $2.06 Get the Latest News and Ratings for TSHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. 10/31/202417,640,000 shares $29.81 million -14.8%N/A8.1 $1.69 10/15/202420,700,000 shares $40.37 million +0.3%N/A13.9 $1.95 9/30/202420,640,000 shares $41.49 million +4.1%N/A13.7 $2.01 9/15/202419,830,000 shares $45.41 million -8.5%N/A9.5 $2.29 8/31/202421,660,000 shares $48.52 million +4.2%N/A9.5 $2.24 8/15/202420,780,000 shares $47.59 million -10.5%N/A8.3 $2.29 7/31/202423,210,000 shares $51.29 million +11.5%N/A8.9 $2.21 7/15/202420,810,000 shares $50.78 million +54.7%N/A7.9 $2.44 6/30/202413,450,000 shares $30.13 million -8.6%N/A4.9 $2.24 6/15/202414,720,000 shares $58.44 million -8.7%N/A6.3 $3.97 5/31/202416,120,000 shares $55.29 million -5.4%N/A6.7 $3.43 5/15/202417,040,000 shares $52.99 million +0.8%N/A6.4 $3.11 4/30/202416,910,000 shares $41.09 million +5.2%N/A6.1 $2.43 4/15/202416,070,000 shares $42.75 million -5.4%N/A5.9 $2.66 3/31/202416,990,000 shares $48.76 million +7.5%N/A6.1 $2.87 3/15/202415,810,000 shares $36.36 million +13.9%N/A6 $2.30 2/29/202413,880,000 shares $43.86 million -14.9%N/A6.3 $3.16 2/15/202416,300,000 shares $25.92 million -2.9%N/A8.3 $1.59 1/31/202416,780,000 shares $25.51 million -4.1%N/A8 $1.52 1/15/202417,490,000 shares $27.98 million -0.2%N/A7.8 $1.60 12/31/202317,530,000 shares $31.03 million +2.3%N/A7.8 $1.77 12/15/202317,130,000 shares $27.92 million +6.0%N/A8.2 $1.63 11/30/202316,160,000 shares $28.44 million +15.8%N/A7.6 $1.76 11/15/202313,950,000 shares $23.44 million +42.9%N/A5.6 $1.68 10/31/20239,760,000 shares $22.84 million -2.6%N/A1.8 $2.34 10/15/202310,020,000 shares $22.65 million -6.1%N/A1.9 $2.26 9/30/202310,670,000 shares $33.72 million +7.5%N/A2.1 $3.16 9/15/20239,930,000 shares $32.67 million +34.9%N/A2.1 $3.29 8/31/20237,360,000 shares $23.55 million +902.0%N/A1.6 $3.20 8/15/2023734,500 shares $1.60 million -33.2%3.9%0.2 $2.18Trump to unlock 15-figure fortune for America (May 3rd) ? (Ad)We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. But something even more spectacular is bound to happen. And those who know what to expect could make 7/31/20231,100,000 shares $740,520.00 -1.8%3.0%4.4 $0.67 7/15/20231,120,000 shares $773,920.00 -12.5%3.1%4.3 $0.69 6/30/20231,280,000 shares $846,080.00 -10.5%3.5%4 $0.66 6/15/20231,430,000 shares $1.09 million +16.3%3.8%3.7 $0.77 5/31/20231,230,000 shares $859,647.00 +3.4%3.4%3.2 $0.70 5/15/20231,190,000 shares $824,789.00 -31.2%3.2%3 $0.69 4/30/20231,730,000 shares $1.34 million +6.1%4.7%4.1 $0.78 4/15/20231,630,000 shares $1.42 million -15.5%4.5%2.9 $0.87 3/31/20231,930,000 shares $1.54 million -18.2%5.4%3.5 $0.80 3/15/20232,360,000 shares $2.07 million -11.6%6.5%4.4 $0.88 2/28/20232,670,000 shares $2.70 million +19.7%7.3%4.7 $1.01 2/15/20232,230,000 shares $2.41 million +2.3%6.1%3.7 $1.08 1/31/20232,180,000 shares $3.58 million +26.7%6.0%2.7 $1.64 1/15/20231,720,000 shares $3.96 million +25.6%4.7%0.7 $2.30 12/30/20221,370,000 shares $3.10 million +48.0%3.8%0.5 $2.26 12/15/2022925,700 shares $2.13 million +12.3%2.5%0.4 $2.30 11/30/2022824,500 shares $1.82 million -38.5%3.8%0.3 $2.21 11/15/20221,340,000 shares $2.95 million -19.8%6.3%0.6 $2.20 10/31/20221,670,000 shares $2.87 million +73.8%11.3%0.8 $1.72 10/15/2022960,700 shares $1.53 million +8.0%4.1%0.6 $1.59 9/30/2022889,600 shares $1.72 million -5.2%3.8%8.5 $1.93 9/15/2022938,700 shares $2.92 million +5.2%4.0%6.2 $3.11 8/31/2022892,600 shares $2.82 million +3.5%3.8%5.3 $3.16 8/15/2022862,300 shares $3.74 million -7.2%3.7%4 $4.34 7/31/2022929,100 shares $3.78 million -10.7%4.1%3.8 $4.07 7/15/20221,040,000 shares $4.43 million -13.3%4.5%3.9 $4.26 6/30/20221,200,000 shares $4.46 million -26.4%5.2%3.8 $3.72 6/15/20221,630,000 shares $4.91 million -3.6%7.1%4.9 $3.01 5/31/20221,690,000 shares $4.31 million -4.5%7.7%6 $2.55 5/15/20221,770,000 shares $6.09 million +18.0%8.1%6.5 $3.44 4/30/20221,500,000 shares $5.49 million +19.1%7.2%5.4 $3.66 4/15/20221,260,000 shares $6.98 million -64.6%6.1%4.5 $5.54 3/31/20223,560,000 shares $23.21 million +4.1%17.1%15.3 $6.52 3/15/20223,420,000 shares $18.30 million +0.6%16.4%15.9 $5.35 2/28/20223,400,000 shares $21.66 million -6.6%16.4%15.3 $6.37 2/15/20223,640,000 shares $28.50 million +10.0%17.5%17 $7.83 1/31/20223,310,000 shares $26.31 million +9.2%15.9%16.2 $7.95 1/15/20223,030,000 shares $28.88 million +0.7%13.9%15.6 $9.53 12/31/20213,010,000 shares $35.07 million +18.0%14.3%16.8 $11.65 12/15/20212,550,000 shares $36.31 million -1.5%12.1%14.9 $14.24 11/30/20212,590,000 shares $33.62 million +1.2%12.3%17.7 $12.98 11/15/20212,560,000 shares $37.12 million +6.7%12.2%18.4 $14.50 10/29/20212,400,000 shares $37.54 million -4.4%11.0%19.7 $15.64 10/15/20212,510,000 shares $44.88 million -11.3%11.6%27 $17.88 9/30/20212,830,000 shares $52.69 million +3.7%13.0%28.3 $18.62 9/15/20212,730,000 shares $57.00 million No Change12.6%17.6 $20.88 8/31/20212,730,000 shares $54.27 million -0.4%12.7%16.6 $19.88 8/13/20212,740,000 shares $47.62 million -0.7%12.6%14.3 $17.38 7/30/20212,760,000 shares $47.72 million +10.8%12.8%14.1 $17.29 7/15/20212,490,000 shares $48.88 million +31.1%11.6%12.9 $19.63Now I look stupid. Real stupid... (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 6/30/20211,900,000 shares $40.28 million +37.7%9.8%9.9 $21.20 6/15/20211,380,000 shares $35.85 million -11.5%6.9%9.7 $25.98 5/28/20211,560,000 shares $35.10 million +9.9%7.8%12.7 $22.50 5/14/20211,420,000 shares $29.71 million +5.2%7.1%14.7 $20.92 4/30/20211,350,000 shares $33.75 million +2.3%6.8%16.6 $25.00 4/15/20211,320,000 shares $33.75 million -7.7%6.7%16.4 $25.57 3/31/20211,430,000 shares $29.32 million +7.5%7.2%16.5 $20.50 3/15/20211,330,000 shares $35.98 million +2.3%6.7%12.6 $27.05 2/26/20211,300,000 shares $34.93 million No Change6.6%11.1 $26.87 2/12/20211,300,000 shares $39.55 million +13.0%6.9%11 $30.42 1/29/20211,150,000 shares $33.27 million -8.7%14.9%9.3 $28.93 1/15/20211,260,000 shares $36.16 million No Change16.3%9.4 $28.70 TSHA Short Interest - Frequently Asked Questions What is Taysha Gene Therapies' current short interest? Short interest is the volume of Taysha Gene Therapies shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 21,630,000 shares of TSHA short. 10.85% of Taysha Gene Therapies' shares are currently sold short. Learn More on Taysha Gene Therapies' current short interest. What is a good short interest ratio for Taysha Gene Therapies? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TSHA shares currently have a short interest ratio of 10.0. Learn More on Taysha Gene Therapies's short interest ratio. Which institutional investors are shorting Taysha Gene Therapies? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Taysha Gene Therapies: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Taysha Gene Therapies? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.85% of Taysha Gene Therapies' floating shares are currently sold short. Is Taysha Gene Therapies' short interest increasing or decreasing? Taysha Gene Therapies saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 21,630,000 shares, a drop of 14.3% from the previous total of 25,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Taysha Gene Therapies' short interest compare to its competitors? 10.85% of Taysha Gene Therapies' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Taysha Gene Therapies: Ocular Therapeutix, Inc. (8.30%), Iovance Biotherapeutics, Inc. (28.32%), Syndax Pharmaceuticals, Inc. (23.65%), Wave Life Sciences Ltd. (9.19%), Collegium Pharmaceutical, Inc. (14.66%), Enliven Therapeutics, Inc. (22.94%), Dyne Therapeutics, Inc. (14.06%), Structure Therapeutics Inc. (12.69%), 89bio, Inc. (14.76%), Chimerix, Inc. (4.27%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Taysha Gene Therapies stock? Short selling TSHA is an investing strategy that aims to generate trading profit from Taysha Gene Therapies as its price is falling. TSHA shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Taysha Gene Therapies? A short squeeze for Taysha Gene Therapies occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TSHA, which in turn drives the price of the stock up even further. How often is Taysha Gene Therapies' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TSHA, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies OCUL Short Squeeze IOVA Short Squeeze SNDX Short Squeeze WVE Short Squeeze COLL Short Squeeze ELVN Short Squeeze DYN Short Squeeze GPCR Short Squeeze ETNB Short Squeeze CMRX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TSHA) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSHA Stock Free TSHA Stock Alerts